Prostaglandin E2 vaginal suppository as a midtrimester abortifacient
- 1 September 1974
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 120 (2) , 281-284
- https://doi.org/10.1016/0002-9378(74)90376-7
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Experience with intra-amniotic prostaglandin F2α for abortionAmerican Journal of Obstetrics and Gynecology, 1973
- Induction of therapeutic abortion with a single dose of intra-amniotically administered prostaglandin F2αProstaglandins, 1973
- Intra-amniotic prostaglandin F2α to induce midtrimester abortionAmerican Journal of Obstetrics and Gynecology, 1973
- Midtrimester Abortion Using Prostaglandin F2α, Oxytocin, and Laminaria**Supported by The Upjohn Company, Kalamazoo, Michigan.††Presented at the Twenty-Ninth Annual Meeting of The American Fertility Society, April 5–7, 1973, San Francisco, California.Fertility and Sterility, 1973
- Laminaria augmentation of intra-amniotic prostaglandin F2α for the induction of mid-trimester abortionProstaglandins, 1973
- Oxytocin administration in mid-trimester saline abortionsAmerican Journal of Obstetrics and Gynecology, 1973
- Abortifacient efficacy of intravaginal prostaglandin F2αAmerican Journal of Obstetrics and Gynecology, 1973
- Prostaglandin-oxytocin abortion: A clinical trial on intra-amniotic prostaglandin F2α in combination with intravenous oxytocinProstaglandins, 1972
- THERAPEUTIC ABORTION AND INDUCTION OF LABOUR BY THE INTRAVAGINAL ADMINISTRATION OF PROSTAGLANDINS E2 AND F2αBJOG: An International Journal of Obstetrics and Gynaecology, 1971